Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) COO Sells 20,000 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima sold 20,000 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $39.61, for a total transaction of $792,200.00. Following the transaction, the chief operating officer now directly owns 982,442 shares in the company, valued at $38,914,527.62. This trade represents a 2.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ryan Fukushima also recently made the following trade(s):

• On Monday, December 16th, Ryan Fukushima sold 3,500 shares of Tempus AI stock. The stock was sold at an average price of $40.23, for a total value of $140,805.00.
• On Wednesday, December 11th, Ryan Fukushima sold 120,000 shares of Tempus AI stock. The shares were sold at an average price of $42.51, for a total value of $5,101,200.00.

Tempus AI Stock Performance

NASDAQ:TEM traded down $1.39 during trading on Wednesday, reaching $37.49. The company’s stock had a trading volume of 2,974,666 shares, compared to its average volume of 3,782,261. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $79.49. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The firm has a 50 day moving average of $48.75 and a 200-day moving average of $47.03.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Stifel Nicolaus cut shares of Tempus AI from a “buy” rating to a “hold” rating and lifted their price objective for the company from $45.00 to $65.00 in a report on Monday, November 11th. Loop Capital lifted their price target on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. Piper Sandler reissued a “neutral” rating and set a $70.00 price objective (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Wolfe Research assumed coverage on Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. Finally, Bank of America upped their price target on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.00.

Hedge Funds Weigh In On Tempus AI

Several institutional investors have recently added to or reduced their stakes in TEM. Silverleafe Capital Partners LLC purchased a new position in Tempus AI in the fourth quarter valued at about $533,000. Franklin Resources Inc. lifted its stake in Tempus AI by 1.0% in the third quarter. Franklin Resources Inc. now owns 811,311 shares of the company’s stock valued at $45,920,000 after purchasing an additional 8,387 shares during the last quarter. Tidal Investments LLC bought a new position in Tempus AI during the third quarter valued at $7,633,000. Teachers Retirement System of The State of Kentucky increased its position in Tempus AI by 6.3% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 126,500 shares of the company’s stock worth $7,160,000 after buying an additional 7,500 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Tempus AI by 0.4% in the third quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock valued at $7,537,000 after buying an additional 539 shares during the period. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.